113 related articles for article (PubMed ID: 31169219)
1. Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?
Aksoy A; Elkiran ET; Harputluoglu H; Dagli AF; Isikdogan A; Urakci Z
J Cancer Res Ther; 2019; 15(3):550-555. PubMed ID: 31169219
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
[TBL] [Abstract][Full Text] [Related]
3. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
4. High/positive expression of ERCC1 predicts poor treatment response and survival prognosis in nasopharyngeal carcinoma: A systematic meta-analysis from 21 studies.
Yang L; Wei W; Zhou L; Wang J; Hu G
Medicine (Baltimore); 2019 May; 98(21):e15641. PubMed ID: 31124943
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
Jin H; Xie X; Wang H; Hu J; Liu F; Liu Z; Zhou J; Zhang Y; Xi X; Hu B; Liao Y; Tang J
PLoS One; 2014; 9(7):e101256. PubMed ID: 25025378
[TBL] [Abstract][Full Text] [Related]
7. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
[TBL] [Abstract][Full Text] [Related]
8. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Zhang Z; Jiang C; Hu L
Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
[TBL] [Abstract][Full Text] [Related]
9. Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
Xu S; Yu Y; Rong J; Hu D; Zhang L; Fu S; Yang H; Fan J; Yang L; Wu J
Oncotarget; 2017 May; 8(19):31355-31367. PubMed ID: 28404895
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
Hui EP; Ma BB; Chan KC; Chan CM; Wong CS; To KF; Chan AW; Tung SY; Ng WT; Cheng AC; Lee VH; Chan SL; Loong HH; Kam MK; Leung SF; Ho R; Mo F; Ngan RK; Chan AT
Cancer; 2015 Aug; 121(16):2720-9. PubMed ID: 25946469
[TBL] [Abstract][Full Text] [Related]
11. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
[TBL] [Abstract][Full Text] [Related]
12. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
Liang R; Lin Y; Liu ZH; Liao XL; Yuan CL; Liao SN; Li YQ
Genet Mol Res; 2015 May; 14(2):5804-11. PubMed ID: 26125779
[TBL] [Abstract][Full Text] [Related]
13. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Chan SH; Cheung FM; Ng WT; Choi CW; Cheung KN; Yiu KH; Lee AW
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1414-20. PubMed ID: 20605357
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between expression of ERCC1 and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma].
Li W; Sun Q; Lu M
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):144-6. PubMed ID: 25989663
[TBL] [Abstract][Full Text] [Related]
15. Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.
Benzeid R; Gihbid A; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; El Benna N; Filali Maltouf A; Attaleb M; Chaoui I; Khyatti M; El Mzibri M
Asian Pac J Cancer Prev; 2023 Jan; 24(1):93-99. PubMed ID: 36708557
[TBL] [Abstract][Full Text] [Related]
16. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Sun JM; Ahn MJ; Park MJ; Lee HY; Ahn JS; Lee S; Kang G; Han J; Son YI; Baek CH; Ahn YC; Park K
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):655-60. PubMed ID: 21621119
[TBL] [Abstract][Full Text] [Related]
17. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment.
Jagdis A; Phan T; Klimowicz AC; Laskin JJ; Lau HY; Petrillo SK; Siever JE; Thomson TA; Magliocco AM; Hao D
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1340-5. PubMed ID: 23182703
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]